Enanta Pharmaceuticals, Inc. ENTA
11.88
(0.12)
(1.00%)
as of 25 Sep
- Market cap
- $349.5M
- P/E
- 0.0×
Follow ENTA
| Sep '25 | Sep '24 | Sep '23 | Sep '22 | Sep '21 | Sep '20 | Sep '19 | Sep '18 | Sep '17 | Sep '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 25.24 | 22.61 | 51.15 | 23.14 |
P/S ratio |
3.91 | 3.24 | 2.78 | 12.40 | 11.80 | 7.45 | 5.73 | 7.84 | 8.82 | 5.71 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 161.77 | 17.83 | 61.72 | 18.09 | 16.21 |
P/Operating CF |
(39.36) | (21.08) | (10.18) | (68.80) | (54.51) | (59.04) | 137.70 | 57.14 | 15.83 | (236.92) |
P/B ratio |
3.95 | 1.70 | 1.01 | 3.33 | 2.87 | 2.00 | 2.54 | 4.11 | 3.01 | 1.87 |
Price to Tangible BV |
3.95 | 1.70 | 1.01 | 3.33 | 2.87 | 2.00 | 2.54 | 4.11 | 3.01 | 1.87 |
EV/Sales |
1.02 | (0.44) | (1.89) | 9.51 | 9.29 | 4.30 | 4.10 | 6.34 | 6.65 | 3.33 |
EV/EBITDA |
0.00 | 0.25 | 1.09 | 0.00 | 0.00 | 0.00 | 23.59 | 14.56 | 24.89 | 8.63 |
EV/Operating CF |
(3.45) | 0.38 | 1.45 | (9.67) | (12.89) | 74.24 | 11.78 | 44.86 | 12.98 | 8.20 |
EV/FCF |
(2.07) | 0.31 | 1.34 | (9.43) | (12.75) | 93.25 | 12.75 | 49.96 | 13.63 | 9.45 |
Quick Ratio |
4.03 | 5.00 | 6.52 | 10.00 | 8.43 | 17.52 | 17.10 | 23.46 | 11.17 | 28.26 |
Current Ratio |
4.21 | 5.21 | 6.73 | 10.45 | 8.82 | 18.08 | 17.77 | 23.74 | 11.33 | 29.43 |
Net Debt/EBITDA |
2.35 | 2.06 | 2.69 | 2.08 | 2.34 | 10.26 | (9.40) | (3.43) | (8.15) | (6.18) |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.20 | 0.16 | 0.19 | 0.21 | 0.21 | 0.25 | 0.45 | 0.56 | 0.34 | 0.33 |
Operating CF/Net income |
0.24 | 0.68 | 0.77 | 0.70 | 0.89 | (0.20) | 1.54 | 0.41 | 2.97 | 1.65 |
Capex/Depreciation |
(2.53) | (14.98) | 18.68 | (0.51) | (0.14) | (0.37) | 5.03 | (1.77) | (0.88) | (1.49) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (84.63%) | (67.17%) | (49.74%) | (33.79%) | (18.48%) | (7.88%) | 10.83% | 20.70% | 6.20% | 8.56% | |
| (24.91%) | (27.67%) | (31.95%) | (29.91%) | (17.08%) | (7.41%) | 10.26% | 19.42% | 5.83% | 8.22% | |
ROIC |
0.00% | 0.00% | 0.00% | (107.35%) | (44.06%) | (37.75%) | 18.04% | 64.99% | 19.72% | 32.21% |
Return on Tangible Assets |
(42.83%) | (42.20%) | (35.98%) | (42.27%) | (27.35%) | (8.59%) | 11.89% | 19.30% | 7.88% | 9.33% |
Average Days of Receivables |
38.45 | 208.55 | 182.57 | 207.73 | 228.73 | 108.88 | 91.27 | 118.72 | 37.68 | 53.10 |
Research and Development Expense of Revenue |
163.40% | 194.39% | 206.46% | 190.95% | 179.36% | 111.66% | 69.31% | 45.91% | 55.88% | 45.84% |
Selling, General and Administrative Expense of Revenue |
67.25% | 85.53% | 66.77% | 52.79% | 33.52% | 22.34% | 12.79% | 11.34% | 20.18% | 19.22% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
28.42% | 39.62% | 35.62% | 31.30% | 21.62% | 15.98% | 9.37% | 7.67% | 12.71% | 10.60% |
Graham Net Nets |
(0.05) | 0.24 | 0.81 | 0.24 | 0.24 | 0.45 | 0.32 | 0.22 | 0.23 | 0.44 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 35.56 | 41.37 | 18.20 | 19.21 |
Earnings Yield |
(32.00%) | (52.90%) | (60.72%) | (11.39%) | (6.88%) | (3.91%) | 3.96% | 4.42% | 1.96% | 4.32% |
Free Cash Flow Yield |
(12.60%) | (44.12%) | (51.01%) | (8.13%) | (6.17%) | 0.62% | 5.61% | 1.62% | 5.53% | 6.17% |
Revenue per Share |
3.06 | 3.20 | 3.78 | 4.18 | 4.81 | 6.14 | 10.48 | 10.73 | 5.39 | 4.66 |
Operating CF per Share |
(0.90) | (3.72) | (4.92) | (4.11) | (3.47) | 0.36 | 3.65 | 1.52 | 2.76 | 1.89 |
Capex per Share |
(0.60) | (0.85) | (0.43) | (0.10) | (0.04) | (0.07) | (0.28) | (0.15) | (0.13) | (0.25) |
Free Cash Flow per Share |
(1.51) | (4.57) | (5.35) | (4.22) | (3.51) | 0.28 | 3.37 | 1.36 | 2.63 | 1.64 |
Cash per Share |
8.85 | 11.76 | 17.64 | 12.10 | 12.10 | 19.39 | 17.12 | 16.03 | 11.73 | 11.10 |
Shareholders Equity per Share |
3.03 | 6.09 | 10.34 | 15.60 | 19.80 | 22.85 | 23.62 | 20.45 | 15.82 | 14.26 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
3.03 | 6.09 | 10.34 | 15.60 | 19.80 | 22.85 | 23.62 | 20.45 | 15.82 | 14.26 |
Free Cash Flow |
(32.17) | (96.71) | (112.21) | (86.91) | (70.75) | 5.64 | 66.00 | 26.24 | 50.15 | 31.07 |
Working Capital |
155.78 | 242.32 | 360.00 | 281.89 | 282.85 | 412.68 | 379.24 | 364.36 | 216.84 | 224.27 |
Capital Expenditures |
(12.90) | (17.95) | (9.06) | (2.12) | (0.75) | (1.44) | (5.42) | (2.98) | (2.51) | (4.74) |
Net Current Asset Value |
(11.68) | 52.01 | 177.25 | 257.64 | 279.66 | 406.29 | 374.51 | 359.84 | 212.86 | 220.82 |
EV/EBIT |
0.00 | 0.24 | 1.09 | 0.00 | 0.00 | 0.00 | 22.90 | 14.84 | 27.76 | 9.52 |
Capex to Sales |
0.20 | 0.27 | 0.11 | 0.02 | 0.01 | 0.01 | 0.03 | 0.01 | 0.02 | 0.05 |
Net Profit Margin |
(125.36%) | (171.58%) | (168.95%) | (141.31%) | (81.38%) | (29.53%) | 22.60% | 34.82% | 17.23% | 24.55% |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 32.03 | 18.34 | 36.85 | 16.33 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.14 | 0.04 | (0.04) | 0.67 | 0.92 | 0.46 | (0.10) | 0.20 | 0.35 | 0.40 |
Cash ROIC |
(21.56%) | (29.52%) | (19.62%) | (15.94%) | (11.80%) | (0.18%) | 7.58% | 2.97% | 8.49% | 5.79% |
Accounts Receivable Turnover |
2.87 | 1.73 | 1.79 | 1.57 | 1.99 | 2.79 | 3.46 | 5.31 | 8.77 | 6.18 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | 0.00 | 0.00 | — | — | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | 0.00 | 0.00 | — | — | — | — | — | — |
Average Receivables |
22.76 | 39.13 | 44.33 | 54.93 | 48.68 | 43.92 | 59.26 | 38.91 | 11.73 | 14.28 |
Average Payables |
4.98 | 6.05 | 5.05 | 7.77 | 7.64 | 6.21 | 5.72 | 4.23 | 3.55 | 2.46 |
Average Assets |
328.69 | 419.46 | 418.84 | 407.10 | 462.46 | 487.98 | 452.03 | 370.43 | 303.96 | 263.65 |
Average Common Equity |
96.77 | 172.77 | 269.03 | 360.38 | 427.50 | 459.04 | 428.09 | 347.68 | 285.81 | 253.05 |
Columns are period end dates